background
chronic
lung
allograft
dysfunct
clad
major
caus
allograft
loss
postlung
transplant
prior
studi
examin
associ
respiratori
viru
infect
rvi
clad
limit
older
diagnost
techniqu
studi
design
case
number
examin
associ
symptomat
rvi
clad
use
modern
diagnost
techniqu
larg
contemporari
cohort
lung
transplant
recipi
ltr
method
retrospect
assess
clinic
variabl
includ
acut
reject
cytomegaloviru
pneumonia
upper
lower
rvi
primari
endpoint
clad
determin
independ
review
ltr
singl
univers
transplant
program
univari
multivari
cox
model
use
analyz
relationship
rvi
clad
timedepend
manner
incorpor
differ
period
risk
follow
rvi
diagnosi
result
fifti
patient
diagnos
clad
median
week
posttransplant
episod
rvi
multivari
analysi
reject
rvi
independ
associ
clad
adjust
hazard
ratio
confid
interv
p
p
respect
associ
rvi
clad
stronger
proxim
rvi
episod
p
p
p
multivari
analysi
month
follow
rvi
respect
conclus
symptomat
rvi
independ
associ
develop
clad
increas
risk
shorter
time
period
follow
rvi
prospect
studi
character
virolog
determin
clad
defin
underli
mechan
warrant
sever
studi
examin
role
respiratori
viru
infect
rvi
develop
clad
associ
report
mani
studi
tabl
includ
studi
specif
assess
associ
rvi
cladbo
use
either
univari
multivari
statist
analysi
studi
import
limit
includ
small
sampl
size
retrospect
design
short
followup
durat
nonblind
assess
key
endpoint
ie
clad
use
nonconsensu
definit
clad
lack
modern
diagnost
virolog
techniqu
inclus
specif
virus
limit
statist
analys
tabl
pool
analysi
studi
rvi
bo
vu
et
al
unabl
confirm
associ
mainli
due
heterogen
studi
major
limit
design
diagnost
techniqu
definit
address
limit
prior
studi
examin
associ
rvi
clad
rel
larg
contemporan
cohort
ltr
includ
patient
diagnos
rvi
use
modern
molecular
assay
appli
systemat
recent
publish
consensu
definit
clad
assess
clad
use
blind
review
use
timedepend
model
multivari
analys
control
factor
previous
associ
clad
base
prior
clinic
studi
anim
model
experiment
data
suggest
risk
clad
may
higher
initi
period
rvi
also
model
associ
rvi
clad
assum
differ
durat
risk
follow
rvi
retrospect
assess
cohort
consecut
adult
patient
receiv
first
lung
transplant
univers
washington
medic
center
uwmc
januari
may
clinic
variabl
endpoint
collect
year
recent
transplant
patient
allow
possibl
maximum
durat
followup
year
first
patient
includ
minimum
year
last
patient
includ
univers
washington
comprehens
electron
health
record
system
patient
demograph
clinic
laboratori
inform
collect
via
medic
record
review
use
standard
data
collect
form
train
personnel
blind
primari
endpoint
clad
univers
washington
institut
review
board
approv
studi
patient
either
recipi
donor
seroposit
cytomegaloviru
cmv
receiv
month
intraven
iv
ganciclovir
oral
valganciclovir
follow
chronic
acyclovir
prophylaxi
cmv
recipi
donor
seroneg
patient
receiv
chronic
acyclovir
prophylaxi
monitor
cmv
viremia
done
blood
quantit
polymeras
chain
reaction
pcr
discontinu
prophylaxi
weekli
month
everi
week
month
monthli
year
cmv
diseas
clinic
suspect
routin
induct
therapi
given
basiliximab
mainten
immunosuppress
consist
prednison
calcineurin
inhibitor
gener
tacrolimu
antimetabolit
gener
mycophenol
mofetil
mycophenol
acid
routin
surveil
bronchoscopi
evalu
reject
perform
studi
period
patient
clinic
suspect
reject
underw
bronchoscopi
bronchoalveolar
lavag
bal
transbronchi
biopsi
episod
acut
reject
defin
biopsi
lung
tissu
demonstr
grade
higher
reject
patient
receiv
highdos
methylprednisolon
biopsi
assess
accord
intern
societi
heart
lung
transplant
guidelin
standard
treatment
acut
reject
methylprednisolon
g
iv
day
refractori
reject
antithymocyt
globulin
gener
use
although
second
cours
methylprednisolon
may
use
base
clinician
discret
standard
protocol
outpati
followup
initi
hospit
discharg
weekli
week
everi
week
month
everi
month
month
posttransplant
everi
month
depend
distanc
transplant
center
involv
local
pulmonologist
formal
spirometri
perform
clinic
visit
clinic
indic
patient
instruct
perform
home
spirometri
notifi
team
decreas
forc
expiratori
volum
second
rvi
test
done
evalu
compat
clinic
sign
symptom
radiograph
abnorm
surveil
test
asymptomat
patient
perform
nasal
swab
wash
sputum
bal
specimen
test
respiratori
viru
rna
use
either
direct
fluoresc
antibodi
fa
cultur
laboratorydevelop
pcr
assay
test
follow
virus
respiratori
syncyti
viru
rsv
parainfluenza
influenza
b
adenoviru
coronaviru
rhinoviru
metapneumoviru
bocaviru
previous
describ
pcr
platform
throughout
entir
studi
period
routin
test
respiratori
sampl
includ
pcr
respiratori
viral
episod
defin
upper
nasal
swab
nasal
wash
lower
sputum
bal
respiratori
specimen
posit
respiratori
viru
cultur
fa
pcr
patient
upper
lower
respiratori
tract
specimen
posit
categor
lower
respiratori
tract
infect
lrti
patient
test
posit
subsequ
rvi
initi
infect
new
viral
episod
defin
least
month
pass
initi
posit
specimen
specif
respiratori
viru
pathogen
least
test
neg
initi
respiratori
viru
follow
newli
posit
test
viru
clad
diagnos
base
routin
serial
spirometri
monitor
bo
defin
patient
prior
baselin
best
averag
two
best
valu
least
week
rclad
defin
forc
vital
capac
fvc
patient
baselin
best
fvc
addit
meet
criteria
bo
persist
least
week
improv
measur
time
futur
two
transplant
pulmonologist
independ
evalu
patient
clad
case
differ
assess
review
primari
data
reach
consensu
diagnosi
altern
explan
decreas
spirometri
airway
stenosi
investig
chart
review
present
time
decreas
spirometr
valu
patient
consid
clad
time
cmv
pneumonia
diagnos
base
posit
shell
vial
andor
posit
viral
cultur
bal
set
compat
symptom
radiograph
find
examin
associ
symptomat
rvi
clad
univari
multivari
model
use
cox
proport
hazard
model
covari
includ
age
type
transplant
bilater
singl
lung
acut
reject
cmv
pneumonia
analyz
cmv
pneumonia
acut
reject
timedepend
indic
variabl
remain
first
episod
cmv
pneumonia
acut
reject
durat
person
followup
rvi
analyz
timedepend
step
function
entir
durat
followup
well
specif
risk
period
month
month
month
follow
diagnosi
rvi
hypothes
relationship
rvi
clad
would
greater
shorter
time
period
base
wane
immun
respons
rvi
time
primari
outcom
develop
clad
secondari
outcom
composit
endpoint
clad
death
kaplanmei
method
use
estim
graph
probabl
clad
phenotyp
bo
rclad
proport
hazard
assumpt
test
use
plot
schoenfeld
residu
analys
perform
use
stata
softwar
version
stata
corpor
colleg
station
texa
total
consecut
patient
receiv
first
lung
transplant
uwmc
januari
may
includ
tabl
show
patient
characterist
signific
differ
demograph
patient
rvi
without
data
shown
clad
diagnos
median
time
week
interquartil
rang
iqr
week
posttransplant
supplementari
figur
show
kaplanmei
curv
overal
surviv
overal
surviv
cohort
report
among
lung
transplant
center
unit
state
followup
period
patient
die
oneyear
surviv
median
time
death
week
iqr
week
last
follow
mortal
higher
patient
clad
vs
without
clad
figur
show
kaplanmei
curv
develop
clad
bo
rclad
separ
definit
clad
requir
document
decreas
least
least
week
howev
confirm
function
declin
perman
also
assess
later
time
point
among
patient
diagnos
clad
pulmonari
function
test
pft
inform
least
month
follow
clad
diagnosi
patient
drop
valu
sustain
continu
meet
criteria
clad
similarli
pft
valu
patient
month
followup
clad
diagnosi
also
persist
spirometri
find
consist
clad
total
viral
episod
diagnos
patient
tabl
detail
characterist
rvi
episod
median
time
first
rvi
week
iqr
week
nine
viral
episod
viru
isol
virus
rhinoviru
virus
virus
total
virus
isol
figur
kaplanmei
curv
show
time
develop
first
rvi
follow
transplant
among
patient
clad
rvi
preced
clad
diagnosi
compar
patient
remain
cladfre
followup
analyz
relationship
sever
factor
clad
univari
multivari
analys
timedepend
manner
model
period
risk
month
month
month
ever
ie
last
followup
rvi
univari
multivari
analysi
rvi
model
risk
period
independ
associ
develop
clad
tabl
associ
stronger
shorter
model
period
risk
confirm
previous
report
associ
acut
reject
develop
clad
tabl
secondari
endpoint
composit
endpoint
clad
death
show
similar
trend
primari
endpoint
univari
multivari
analysi
higher
hazard
ratio
hr
rvi
month
progress
declin
hr
time
rvi
increas
hr
confid
interv
ci
p
vs
hr
ci
p
month
vs
month
postrvi
respect
also
analyz
associ
gastroesophag
reflux
diseas
gerd
clad
use
method
first
requir
posit
ph
probe
test
gerd
diagnosi
second
includ
anyon
clinic
diagnosi
gerd
statist
signific
associ
seen
univari
analysi
data
shown
either
definit
gerd
therefor
gerd
includ
final
model
also
interest
whether
clad
phenotyp
strongli
associ
rvi
rclad
vs
bo
number
small
preclud
formal
analysi
overal
higher
percentag
rclad
patient
least
preced
viral
episod
compar
bo
vs
respect
larg
contemporari
cohort
ltr
underw
symptomguid
test
rvi
use
molecular
diagnost
method
found
high
rate
rvi
independ
associ
symptomat
rvi
clad
associ
rvi
clad
stronger
shorter
model
period
risk
also
present
followup
time
consid
demonstr
first
time
strength
associ
symptomat
rvi
clad
significantli
influenc
time
eg
proxim
rvi
episod
clad
diagnosi
stronger
associ
first
sever
month
rvi
import
implic
futur
trial
antivir
agent
includ
power
trial
endpoint
clad
studi
also
address
sever
import
limit
prior
studi
significantli
extend
understand
role
rvi
clad
provid
strong
rational
conduct
larg
prospect
studi
character
specif
virolog
determin
mechanist
link
rvi
clad
sever
prior
studi
assess
associ
rvi
bo
tabl
magnusson
et
al
found
associ
bo
rvi
odd
ratio
ci
p
retrospect
cohort
studi
howev
consid
lrti
base
larg
surveil
bal
cohort
small
ltr
rvi
follow
ltr
year
outcom
rvi
episod
record
first
year
posttransplant
khalifah
et
al
also
report
associ
rvi
bo
univari
multivari
analys
retrospect
cohort
studi
assess
virus
use
nonmolecular
method
distinguish
bo
rclad
use
blind
review
assess
clad
includ
rel
case
rvi
bill
et
al
found
relationship
rvi
clad
overal
subanalysi
demonstr
associ
highgrad
bo
lrti
mani
limit
khalifah
et
al
contrast
studi
milston
et
al
report
associ
howev
sampl
size
small
bo
case
rvi
thu
prior
studi
rel
heterogen
signific
limit
might
explain
discrep
present
studi
studi
import
strength
examin
larg
cohort
patient
among
largest
assess
issu
diagnos
rvi
use
modern
molecular
diagnost
techniqu
detect
larg
number
respiratori
virus
use
timedepend
multivari
analys
control
factor
associ
previous
clad
also
model
differ
period
risk
provid
insight
mechan
underli
relationship
rvi
clad
importantli
primari
endpoint
clad
assign
use
recent
develop
consensu
definit
blind
transplant
pulmonologist
also
acknowledg
certain
limit
includ
retrospect
singlecent
studi
design
despit
comprehens
medic
record
close
followup
exclud
miss
data
thu
rate
rvi
consid
minim
estim
patient
may
diagnos
outsid
medic
center
abl
assess
factor
link
clad
includ
pseudomona
pneumonia
andor
colon
small
conidi
form
aspergillu
howev
consensu
proven
risk
factor
clad
studi
size
larg
enough
permit
assess
risk
clad
associ
specif
viral
organ
larg
enough
assess
differ
clad
phenotyp
bo
rclad
although
found
independ
associ
symptomat
rvi
clad
possibl
rvi
could
simpli
marker
patient
areotherwis
predispos
clad
rather
thanacaus
clad
sever
line
evid
suggest
rvi
might
underrecogn
contributor
rather
marker
substanti
proport
clad
case
summar
tabl
rvi
link
clad
sever
prior
studi
rvi
rel
common
ltr
signific
proport
case
detect
sensit
method
asymptomat
importantli
symptomat
asymptomat
rvi
link
clad
addit
vitro
anim
studi
identifi
specif
biolog
plausibl
mechan
rvi
could
mediat
clad
rvimedi
regulatori
tcell
dysfunct
lead
augment
innat
allo
autoimmun
pathway
possibl
mechanist
pathway
explain
causal
link
rvi
clad
final
small
clinic
trial
novel
antivir
sirna
specif
rvi
rsv
ltr
demonstr
reduc
risk
clad
group
random
activ
rsv
therapi
total
epidemiolog
experiment
data
consist
causal
associ
rvi
clad
summari
studi
address
mani
limit
prior
studi
add
significantli
bodi
evid
link
rvi
develop
clad
associ
relev
rvi
could
repres
distinct
diagnos
potenti
treatabl
major
caus
allograft
dysfunct
loss
ltr
associ
confirm
futur
prospect
studi
minimum
could
identifi
specif
patient
increas
risk
develop
clad
could
enter
trial
prevent
treatment
strategi
develop
new
antivir
sever
respiratori
virus
possibl
directli
test
hypothesi
rvi
caus
clad
mean
intervent
control
trial
prior
embark
studi
imper
care
character
virolog
determin
mechan
underli
clad
order
aid
design
intervent
trial
studi
strongli
suggest
associ
symptomat
rvi
clad
propos
larg
multicent
prospect
natur
histori
studi
care
virolog
clinic
assess
mechanist
studi
logic
next
step
better
understand
role
respiratori
virus
pathogenesi
clad
futur
prospect
studi
critic
devis
ration
strategi
improv
longterm
patient
graft
surviv
ltr
supplementari
materi
avail
http
cidoxfordjournalsorg
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
author
